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Abstract
Background: Autophagy has been shown recently to play an important role in the intracellular
survival of several pathogenic bacteria. In this study, we investigated the effect of a novel small-
molecule autophagy-inducing agent, AR-12, on the survival of Francisella tularensis, the causative
bacterium of tularemia in humans and a potential bioterrorism agent, in macrophages.
Methods and results: Our results show that AR-12 induces autophagy in THP-1 macrophages,
as indicated by increased autophagosome formation, and potently inhibits the intracellular survival
of F. tularensis (type A strain, Schu S4) and F. novicida in macrophages in association with increased
bacterial co-localization with autophagosomes. The effect of AR-12 on intracellular F. novicida was
fully reversed in the presence of the autophagy inhibitor, 3-methyl adenine or the lysosome
inhibitor, chloroquine. Intracellular F. novicida were not susceptible to the inhibitory activity of AR-
12 added at 12 h post-infection in THP-1 macrophages, and this lack of susceptibility was
independent of the intracellular location of bacteria.
Conclusion: Together, AR-12 represents a proof-of-principle that intracellular F. tularensis can be
eradicated by small-molecule agents that target innate immunity.
Background
Macroautophagy (called autophagy hereafter) is a cellular
response of eukaryotic cells to a number of deleterious
stimuli including nutrient deprivation, organelle damage
and accumulation of unfolded proteins [1]. In addition,
evidence indicates that autophagy also aids in controlling
infection by certain microorganisms, including viruses,
bacteria and parasites [2]. Indeed, the induction of
autophagy by amino acid starvation, interferons or phar-
macological agents has been shown to decrease the sur-
vival of various intracellular bacteria, including
Mycobacterium tuberculosis, Group A Streptococcus pyrogenes
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and Salmonella typhimurium [3-5]. Thus, the induction of
autophagy may represent a viable therapeutic approach
for the treatment of infections caused by intracellular bac-
teria that is worthy of further investigation.
Francisella tularensis is a Gram negative, facultative cocco-
bacillus that causes the zoonotic disease, tularemia [6,7].
Depending on the route of infection, F. tularensis can lead
to different forms of tularemia. Inhalation of bacteria
causes the most severe form of the disease, pneumonic
tularemia, which has a mortality rate as high as 60 percent
in the absence of appropriate treatment [6-8]. Because of
the potential to inflict severe disease in a large number of
people with an aerosolized form of the bacteria, F. tularen-
sis is classified in Category A of potential biological war-
fare agents by the U.S. Centers for Disease Control and
Prevention [9,10]. Moreover, in the absence of an U.S.
Food and Drug Administration-approved vaccine and in
light of the potential existence of antibiotic-resistant
strains of F. tularensis created in the early 1990s [9-11], the
development of new antibacterial agents with novel
mechanisms against F. tularensis has become a priority for
public safety.
In infected hosts, F. tularensis is primarily found in the
macrophage [8]. After entry into macrophages by phago-
cytosis, F. tularensis blocks the fusion of Francisella-con-
taining phagosomes with lysosomes and later escapes into
the cytosol where it proliferates to a high number [12-14].
Subsequently, F. tularensis induces infected host cells to
undergo apoptosis or pyroptosis, which leads to release of
bacteria and infection of new cells [15,16]. In addition to
this cytosolic proliferation and induction of host cell
death, intracellular F. tularensis have also been found to
reside in Francisella-containing vacuoles (FCVs) at later
stages of intracellular infection. The FCVs are double-
membraned vacuoles, which microscopically appear sim-
ilar to the autophagosmes formed during autophagy
[17,18]. Blockage of autophagy decreased the colocaliza-
tion of intracellular F. tularensis with FCVs in infected host
cells [17,19]. Moreover, F. tularensis mutants which are
incapable of escaping from phagosomes were found to be
surrounded by autophagosome-like vacuoles at the early
stage of intracellular infection, suggesting that autophagy
could play an important role in controlling intracellular
growth of Francisella within phagosomes [18,19].
In this study, we demonstrate that AR-12 (a.k.a. OSU-
03012), a novel small-molecule autophagy-inducing
agent, is able to eradicate intracellular F. tularensis ssp.
novicida (called F. novicida hereafter) and F. tularensis (type
A strain Schu S4) without causing cytotoxicity to the host
cells. Furthermore, inhibition of autophagosome forma-
tion and lysosomal degradation completely reversed this
AR-12-induced killing of intracellular F. tularensis, indicat-
ing that the anti-Francisella activity of this agent is medi-
ated primarily through an autophagy-dependent
mechanism. Together, our findings show that induction
of autophagy is an effective approach for the control of
intracellular F. tularensis in macrophages and suggest that
AR-12 can serve as a scaffold for the development of more
potent autophagy-inducing antibacterial agents.
Materials and methods
Bacteria
F. novicida strain U112 and F. tularensis strain Schu S4
(type A) were used throughout this study. Construction of
a quadruplicate acid phosphatase mutant strain
(JSG2871) of F. novicida was described in a previous study
[18]. Experiments involving Schu S4 were conducted in a
CDC select agent-approved BSL-3 laboratory at The Ohio
State University. Bacteria were grown at 37°C on choco-
late II agar (Becton, Dickinson and Company, Franklin
Lakes, NJ) or in tryptic soy broth (TSB; Becton, Dickinson
and Company) supplemented with 0.025% (w/v) iron
(III) pyrophosphate (Sigma-Aldrich, St. Louis, MO) and
0.1% (w/v) cysteine hydrochloride (MP Biomedicals,
Solon, OH).
Macrophages
The THP-1 human monocytic leukemia cell line was
maintained in RPMI 1640 medium (GIBCO-BRL, Invitro-
gen Corp., Carlsbad, CA) containing 10% fetal bovine
serum (FBS; GIBCO-BRL). To induce differentiation, THP-
1 cells were treated with 20 nM 12-O-tetradecanoylphor-
bol 13-acetate (TPA; Sigma-Aldrich, St. Louis, MO) for 48
h. Cells were washed twice with pre-warmed PBS and cul-
tured with fresh RPMI 1640 medium containing 10% FBS
at 37°C in a humidified incubator containing 5% CO2
prior to experimentation.
Reagents and antibodies
AR-12 was synthesized in-house as described previously
with purity exceeding 99% as shown by nuclear magnetic
resonance spectroscopy (300 MHz) [20]. 3-Methyl ade-
nine (3-MA) and chloroquine were obtained from Sigma-
Aldrich. Stock solutions of AR-12 and chloroquine were
prepared in DMSO and diluted in culture medium for
treatment of cells (final concentration of DMSO, 0.1%).
3-MA was directly dissolved in cell culture medium and
freshly prepared before each experiment. The following
antibodies were used in this study: anti-LC3 and anti-LC3
II (MBL, Woburn, MA); anti-Francisella tularensis ssp. novi-
cida (ImmunoPrecise, Victoria, BC); Alexa Red-conjugated
goat anti-mouse IgG and FITC-conjugated goat anti-
mouse IgG (Invitrogen, Carlsbad, CA).Journal of Biomedical Science 2009, 16:110 http://www.jbiomedsci.com/content/16/1/110
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Assay for intracellular survival of Francisella in 
macrophages
F. novicida and F. tularensis (type A strain Schu S4) grown
overnight on chocolate II agar plates were suspended in
PBS to a concentration of approximately 1010 CFU/ml (as
estimated by an O.D. of 1.0 at 600 nm). To facilitate bac-
terial uptake by macrophages, bacteria were opsonized
with human complement by incubating in RPMI-1640
medium containing 10% normal human serum for 30
min at 37°C with agitation [21]. Bacteria were added at a
MOI of 50 to TPA-differentiated THP-1 macrophages
seeded in 24-well plates at 2.5 × 105 cells/well [18]. Plates
were cultured with rocking for 30 min at 37°C in a
humidified incubator containing 5% CO2, and then incu-
bated for an additional 1.5 h. Bacteria and macrophages
were exposed to 50 μg/ml of gentamicin for 30 min, fol-
lowed by two washes with pre-warmed PBS to remove
killed extracellular bacteria [15]. Infected macrophages
were then treated in triplicate with various concentrations
of AR-12 for 3 h, after which culture medium was col-
lected from each well and macrophages lysed with 500 μl
of 0.1% sodium deoxycholate in PBS at 37°C for 5 min to
release intracellular bacteria [14]. Bacteria present in the
collected culture medium, either as free bacteria or within
unattached macrophages, were harvested by centrifuga-
tion at 16,000 × g for 5 min, followed by resuspension in
the macrophage lysates obtained previously. Cell lysates
were serially diluted with PBS and spread onto agar plates
supplemented with 0.025% (w/v) iron (III) pyrophos-
phate and 0.1% (w/v) cysteine hydrochloride, or choco-
late II agar plates. CFU were calculated after incubation for
24 h at 37°C. Survival of intracellular bacteria in drug-
treated macrophages was calculated as a percentage of that
in control (untreated) cells.
Immunofluorescence microscopy
To visualize intracellular F. novicida, bacteria were trans-
formed with a green fluorescent protein (GFP) expressing
plasmid (pKK214) as described in a previous study [22].
Infection of THP-1 macrophages with GFP-labeled F. novi-
cida was performed as described above for unmodified F.
novicida. After treatment with vehicle or AR-12, cells were
washed three times with cold PBS, fixed with 4% formal-
dehyde (Sigma) in PBS for 20 min at 25°C, and then per-
meabilized with 0.5% Triton X-100 in PBS for 15 min
followed by blocking with 3% bovine serum albumin
(BSA) in PBS overnight at 4°C. After three washes with
PBS, infected macrophages were incubated with primary
antibody in PBS containing 1% BSA for 1 h at 25°C and
then with Alexa Red- or FITC-conjugated secondary anti-
body for 1 h at 25°C. Macrophage nuclei were stained
with 4'-6-diamidino-2-phenylindole (DAPI) contained in
the Vectashield Mounting Medium (Vector Laboratories,
Burlingame, CA). The slides were examined using a Nikon
TE300 wide-field fluorescent microscope equipped with a
digital camera (CoolSnap HQ, Roper Scientific, Tucson,
AZ) or a Zeiss LSM 510 confocal laser scanning micro-
scope system. To assess co-localization of intracellular
bacteria with autophagosomes, three-dimensional images
acquired by confocal microscopy were utilized to ensure
the direct contact of bacteria with autophagosomes.
Immunoblotting
Cells were washed with cold PBS, then suspended in M-
PER protein extraction reagent (Pierce, 7 Rockford, IL),
vortex vigorously and incubated on ice for 10 min. After
centrifugation at 14,000 × g for 15 min at 4°C, the lysate
supernatants were mixed with 4× Laemmli buffer and
incubated at 95°C for 10 min. Equivalent amounts of
total protein were resolved on a SDS-acrylamide gel (20
μg/lane) and transferred to 0.2 μm nitrocellulose mem-
branes (Gelman, Pall Corp., East Hills, NY). The mem-
branes were blocked with 3% skim milk in TBS for 30 min
and then washed twice with 0.5% Tween-20 in TBS
(TBST). The membrane was incubated with primary anti-
body at the appropriate dilution in TBST for 12 h at 4°C,
washed three times with TBST, incubated with HRP-con-
jugated goat IgG secondary antibody in TBST containing
1% skim milk for 2 h, and then washed three times with
TBST. The immunopositive bands were visualized by
enhanced chemiluminescence (GE Amersham, Piscata-
way, NJ]) followed by exposure of X-ray film (Hyperfilm,
GE Amersham). Quantification of the density of bands
was performed using Gel-Pro Analyzer (V3.1, Media
Cybernetics, Bethesda, MD).
Macrophage viability assay
The effect of AR-12 on macrophage viability was assessed
by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium (MTT) assay [23]. THP-1 macrophages
were seeded into 96-well plates at 2.5 × 104 cells/well
(minimum of six wells per test group) in RPMI 1640
medium supplemented with 10% FBS, and then incu-
bated overnight at 37°C in a humidified incubator con-
taining 5% CO2. The medium from each well was
removed and replaced with fresh 10% FBS-supplemented
RPMI 1640 medium containing various concentrations of
AR-12. Controls received DMSO alone at a concentration
equal to that in drug-treated cells. After 3 h of treatment,
the medium was removed, replaced by 100 μl of 0.5 mg/
ml of MTT in 10% FBS-containing medium, and the cells
were incubated at 37°C for 30 min. Medium was removed
from each well, and the reduced MTT dye was solubilized
in 100 μl/well of DMSO. Absorbance at 570 nm was
determined on a plate reader. The viability of drug-treated
cells was calculated as a percentage of vehicle-treated con-
trol cells, and an IC50 for cell viability was determined by
using CalcuSyn software (Biosoft, Cambridge, UK). In
addition to the MTT assay, the effect of AR-12 on the via-
bility of F. novicida-infected THP-1 macrophages was con-Journal of Biomedical Science 2009, 16:110 http://www.jbiomedsci.com/content/16/1/110
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firmed by the lactate dehydrogenase (LDH) release assay
[24] using the CytoTox 96® Non-Radioactive Cytotoxicity
Assay kit (Promega, Madison, WI, USA).
Extracellular bacterial growth assay
F. novicida grown overnight on a chocolate II agar plate
were suspended in PBS to an O.D. of 1.0 at 600 nm, which
was equivalent to 1010 CFU/ml, and then diluted in mod-
ified TSB to a final concentration of 104 CFU/ml. The bac-
terial suspension was exposed to various concentrations
of AR-12 in triplicate in 96-well plates. Bacterial growth in
each well was monitored spectrophotometrically on a
microplate reader (Molecular Devices, Sunnyvale, CA) at
37°C and a wavelength of 600 nm with readings taken
every 30 min for 8 h.
Statistical analysis
Data are expressed as means ± SD. Group means were
compared using a two-tailed t-test for independent sam-
ples. Differences were considered significant at P < 0.05.
Statistical analyses were performed using SPSS for Win-
dows (Version 16.0; SPSS, Inc. Chicago, IL).
Results
AR-12 induces autophagy in human macrophages without 
causing cytotoxicity
AR-12 is an orally bioavailable small-molecule inhibitor
of phosphoinositide-dependent kinase (PDK)-1 that was
derived by structural modification of the cyclooxygenase-
2 (COX-2) inhibitor, celecoxib, but is devoid of COX-2-
inhibitory activity [20]. In addition to PDK-1 inhibition,
recent findings indicate that AR-12 is capable of inducing
autophagy in a variety of cells at concentrations of 1 - 5
μM [25-27]. Importantly, we recently showed that AR-12
caused the clearance of intracellular Salmonella Typhimu-
rium, in part, through this autophagy-inducing activity
[28]. To assess whether AR-12 can induce autophagy in
human macrophages, THP-1 macrophages were exposed
to 1 μM of AR-12, and then evaluated for evidence of
autophagy by immunocytochemistry and Western blot
analysis. First, the formation of autophagosomes in the
cytosol was visualized by immunofluorescent staining
with antibody against microtubule-associated protein
light chain 3-II (LC3-II), a specific autophagosome
marker. During autophagy, the cytoplasmic form of the
protein, LC3-I, is cleaved and recruited to the autophago-
phore, where LC3-II is generated via site-specific lipida-
tion. As shown in Fig. 1A, AR-12 induced a transient
increase in the number and size of autophagosomes in the
cytosol of human macrophages that peaked at 60 min
after drug exposure. Second, immunoblotting of LC3 pro-
tein in AR-12-treated macrophages also showed a tran-
sient increase in LC3-II levels (Fig. 1B). This fluctuation in
the presence of autophagosomes and LC3-II in AR-12-
treated macrophages indicated that autophagy was acti-
vated and that the subsequent lysosomal degradation of
autophagosomes was unaffected. Although excessive
autophagic activity can lead to cell death, no cytotoxic
effect of AR-12 on THP-1 macrophages was observed after
3 h of treatment with concentrations of up to 10 μM (Fig.
1C). Together, these findings indicate AR-12 is capable of
inducing autophagy in THP-1 macrophages at a concen-
tration that exhibits no cytotoxicity.
AR-12 inhibits intracellular survival of Francisella 
tularensis in human macrophages
To examine whether the autophagy induced by AR-12 is
associated with an increase in colocalization of intracellu-
lar F. novicida with autophagosomes, cells infected with
GFP-labeled F. novicida were treated with vehicle or 1 μM
of AR-12 for 60 min and then probed with LC3-II anti-
body. The colocalization of bacteria with LC3-II-positive
puncta was determined by confocal fluorescence micros-
copy. Data indicated that approximately 15% of F. novic-
ida  in AR-12-treated THP-1 macrophages were co-
localized with LC3-II-positive puncta, compared to 5% in
vehicle-treated macrophages after 1 h of AR-12 treatment
(data not shown). To examine whether this increase in
bacteria-autophagosome colocalization is associated with
reductions in the intracellular survival of F. novicida,
infected THP-1 macrophages were exposed to different
concentrations of AR-12 for 3 h, and then the number of
surviving intracellular bacteria was assessed by CFU
counts. As shown in Fig. 2A, the survival of intracellular F.
novicida was significantly reduced by AR-12 at concentra-
tions ≥1 μM. As AR-12 has not been shown to induce
autophagy at sub-μM concentrations, these data indicate
a correlation between autophagy induction and inhibi-
tion of intracellular bacterial survival in AR-12-treated
THP-1 macrophages. In addition to F. novicida, the effect
of AR-12 on intracellular F. tularensis (type A strain Schu
S4) was also examined. With exposure to various concen-
trations of AR-12 for 3 h, the survival of intracellular Schu
S4 in THP-1 macrophages decreased in a dose-dependent
manner (Fig. 2B). This AR-12-induced intracellular bacte-
rial killing, however, was not attributable to the death of
infected host cells since AR-12 had no appreciable effect
on the viability of bacteria-infected THP-1 macrophages
after 3 h of treatment with concentrations up to 10 μM
(Fig. 2C). A similar lack of cytotoxicity was also observed
at 6 and 12 h of treatment with 5 μM of AR-12 (data not
shown). Confirmatory assays using LDH release as an
indicator of cytotoxicity revealed a similar lack of effect on
the viability of infected THP-1 macrophages (data not
shown). Furthermore, to determine whether this AR-12-
induced clearance of intracellular Francisella from macro-
phages involved a direct action of the drug on bacteria, F.
novicida were exposed to AR-12 during growth in modi-
fied TSB. Figure 2D shows that AR-12 exhibited no direct
inhibitory effect on the growth of F. novicida, suggestingJournal of Biomedical Science 2009, 16:110 http://www.jbiomedsci.com/content/16/1/110
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that the inhibition of intracellular survival of Francisella is
mediated indirectly via effects on host cells. Together,
these findings show that AR-12 is capable of inhibiting
growth of both human-virulent and human-avirulent
subspecies of F. tularensis in human macrophages through
a host cell-directed mechanism.
The inhibitory activity of AR-12 against intracellular 
Francisella is autophagy-dependent
To verify the role of autophagy in AR-12-induced killing
of intracellular Francisella, we assessed the effect of block-
ing autophagy on the anti-Francisella activity of AR-12. 3-
MA suppresses autophagy through inhibition of class III
phosphatidylinositol-3-kinase (PI3K), the enzyme that
catalyzes the production of phosphoinositide-3-phos-
phate, which plays an important role in the formation of
autophagosomes. Treatment of infected THP-1 macro-
phages with 3-MA reversed the inhibitory effect of AR-12
on the survival of intracellular F. novicida (Fig. 3A).
At late stages of the autophagic process, autophagosomes
fuse with lysosomes to form autolysosomes, the contents
of which are subsequently degraded by lysosomal
enzymes. Consequently, to examine whether the blockage
of lysosomal degradation will affect AR-12's anti-Fran-
cisella activity, we utilized chloroquine, an inhibitor of lys-
osomal degradation, to block the degradation of
autophagosomal contents. As shown, the reduction of
Induction of autophagy in THP-1 macrophages by AR-12 Figure 1
Induction of autophagy in THP-1 macrophages by AR-12. (A) AR-12 induced autophagosome formation in uninfected 
THP-1 macrophages. THP-1 cells were induced to differentiate by treatment with 12-O-tetradecanoylphorbol 13-acetate and 
then treated as indicated. Autophagosomes were visualized by immunofluorescence microscopy after staining with antibody 
against LC3-II. Scale bar, 10 μm. (B) AR-12 induced the accumulation of LC3-II in uninfected THP-1 macrophages. Above: West-
ern blot analysis of the time-dependent effect of AR-12 on LC3-II formation in uninfected THP-1 macrophages. β-Actin was 
used as a loading control. Below: The ratio of LC3-II/β-actin in the blot after different time of AR-12 exposure (C) AR-12 did 
not affect the viability of uninfected THP-1 macrophages. Cells were treated with the indicated doses of AR-12 for 3 h and cell 
viability was assessed by the MTT assay. Points, mean; bars, ± SD (n = 6).
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intracellular F. novicida induced by AR-12 was completely
reversed in the presence of 10 μM of chloroquine (Fig.
3B). Together, these findings indicated that autophagy
plays a major role in the eradication of intracellular F.
tularensis by AR-12.
The susceptibility of intracellular Francisella to AR-12 
varies at different time points post-infection
During the course of intracellular infection of macro-
phages,  F. tularensis is located within different cellular
compartments including the phagosome from which it
escapes, the cytosol where it proliferates, and, at later
stages, the FCVs. Mohapatra et al. have demonstrated that
during infection of THP-1 human macrophages with F.
novicida, 98% and 60% of intracellular bacteria reside in
the vacuoles at 2 h and 24 h post-infection, respectively,
while at 12 h post-infection, only about 1% are present in
vacuoles as the vast majority of bacteria have escaped to
the cytosol [18]. To assess whether the inhibitory activity
of AR-12 on the intracellular survival of F. novicida varies
with the intracellular location of bacteria, infected THP-1
Inhibition of intracellular survival of F. tularensis in THP-1  macrophages by AR-12 Figure 2
Inhibition of intracellular survival of F. tularensis in 
THP-1 macrophages by AR-12. (A) Dose-dependent 
effect of AR-12 (3 h treatment) on the intracellular survival of 
F. novicida in THP-1 macrophages. Post-treatment CFU values 
are expressed as a percentage of those in the control group. 
Columns, mean; bars, ± SD (n = 3). *P < 0.05, **P < 0.01. (B) 
Dose-dependent effect of AR-12 (3 h treatment) on the 
intracellular survival of F. tularensis (a type A strain, Schu S4) 
in THP-1 macrophages. Points, mean; bars, ± SD (n = 3). *P < 
0.05, **P < 0.01. (C) AR-12 did not show cytotoxic effect on 
the viability of F. novicida infected THP-1 macrophages. Cells 
infected with F. novicida and treated with the indicated doses 
of AR-12 for 3 h. Cell viability was assessed by the MTT 
assay. Points, mean; bars, ± SD (n = 3). (D) Effect of AR-12 on 
the growth of F. novicida in modified TSB broth. Points, mean; 
bars, ± SD (n = 6).
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macrophages were treated with various doses of AR-12 for
3 h starting at 2.5, 12 and 24 h post-infection, and the sur-
viving intracellular bacteria were enumerated by the CFU
assay. While AR-12 showed potent dose-dependent inhib-
itory activity on intracellular F. novicida at 2.5 h and 24 h
post-infection, no significant inhibition of intracellular
survival was observed at 12 h post-infection (Fig. 4). This
result indicates a lack of inhibitory activity against bacte-
ria at 12 h post-infection, and that AR-12's antibacterial
activity might be specific to Francisella enclosed within
intracellular vacuoles.
To verify whether the intracellular location affects the sus-
ceptibility of intracellular Francisella to AR-12, the effect of
AR-12 on a quadruplicate acid phosphatase deficient
strain (ΔABCH) of F. novicida was examined. The com-
bined deletion of four acid phosphatases (A, B, C and H)
of F. novicida has been shown to impair the ability of bac-
teria to escape the phagosome as these bacteria were dem-
onstrated to always reside in a vacuolar compartment in
THP-1 macrophages at 2, 12 and 24 h post-infection [18].
However, as shown in Figure 4, whereas the intracellular
ΔABCH mutant was susceptible to AR-12 at 2.5 h and 24
h post-infection, it was resistant at 12 h post-infection
comparable to the wild type strain, indicating that the
resistance of intracellular F. novicida to AR-12 at 12 h post-
infection is not due to the intracellular location of bacteria
but rather to another mechanism.
Discussion
Recently, the concept of boosting host defense mecha-
nisms against intracellular pathogens has received wide
attention in the infectious disease arena [29]. From a ther-
apeutic perspective, targeting host immunity with an
orally bioavailable small-molecule agent represents a
novel strategy for antimicrobial therapy. Here we present
findings that provide proof-of-principle of the feasibility
of treating Francisella infection by targeting autophagy in
phagocytes with a small-molecule agent. Our results show
that AR-12 is a potent inhibitor of the intracellular sur-
vival of F. tularensis and activator of autophagy in macro-
phages at concentrations that induce no cytotoxicity in
host macrophages. Although AR-12 has been shown to be
cytotoxic to cancer cells, the antibacterial effects of AR-12
occur at lower concentrations and after shorter treatment
durations. Moreover, it is worth noting that our previous
in vivo evaluations of AR-12 in murine models of cancer
revealed that continuous treatment with AR-12 were well
tolerated and induced no dose-limiting toxicities [30,31]
in association with plasma concentrations of approxi-
mately 2.5 μM (Chen, unpublished data). These findings
suggest that toxicities associated with the levels of AR-12
needed for antibacterial effects, if they occur, will be min-
imal.
Several intracellular bacteria, including Shigella, Legionella
and Burkholderia, are capable of evading autophagic erad-
Susceptibility of intracellular F. novicida to AR-12 varies at different time points post-infection Figure 4
Susceptibility of intracellular F. novicida to AR-12 varies at different time points post-infection. THP-1 macro-
phages were infected with F. novicida (dark bar) or a quadruplicate acid phosphatase deletion mutant (ΔABCH; gray bar) and 
treated with various doses of AR-12 for 3 h beginning at different time points post-infection. The number of surviving intracel-
lular bacteria was determined by the CFU assay. Columns, mean; bars, ± SD (n = 3). *P < 0.05, **P < 0.01.
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ication by inhibiting the activation of autophagy with bac-
terial secretory proteins [32-34]. The findings presented
here indicate that intracellular F. tularensis at 12 h post-
infection is not susceptible to the antibacterial activity of
AR-12; in contrast to the susceptibility seen at 2.5 h and
24 h post-infection. Since AR-12-induced killing of intra-
cellular  Francisella  is mediated primarily through an
autophagy-dependent mechanism, we speculate that bac-
teria evade the antibacterial effect of AR-12 by inhibiting
autophagy activation at 12 h post-infection. This notion is
supported by evidence showing that intracellular infec-
tion with Francisella  down-regulates several autophagy-
related genes in THP-1 human monocytes, including
ATG5, ATG12, ATG16L2, ATG7, ATG4A and class III PI3K
[35,36]. Although these reported data were obtained at 24
h post-infection, we cannot exclude the possibility that
this down-regulation of autophagy by Francisella occurs at
an earlier stage of infection such as after phagocytosis and
exposure to the phagosomal environment. Moreover, our
findings from the use of the quadruplicate acid phos-
phatase mutant strain (ΔABCH) indicate that this resist-
ance to AR-12 involves pathways affecting autophagy or
other aspects of host resistance that are independent of
the intracellular location of the organism. Nonetheless,
the fact that intracellular Francisella  are located within
autophagosomes at late stages of infection suggest that
this autophagy inhibitory activity of the bacteria declines,
resulting in restoration of susceptibility to autophagic
eradication and rendering them sensitive to the antibacte-
rial activity of AR-12.
AR-12 has been reported to inhibit a variety of cellular
enzymes, including PDK-1 and P21 activated kinase-1
(PAK-1), and to induce endoplasmic reticulum (ER) stress
[37-39]. Among these activities, the induction of ER stress
has been shown to contribute to the AR-12-induced acti-
vation of autophagy in cancer cells for which the activity
of PKR-like ER kinase (PERK) was determined to be
important [26]. Activation of PERK, considered to be the
central regulatory kinase for the unfolded protein
response in eukaryotic cells, leads to autophagosome for-
mation through the phosphorylation eIF2α and subse-
quent formation of the Atg5-Atg12(-Atg6) complex
[40,41]. Although important for AR-12-induced
autophagy in cancer cells, it is not known whether PERK
has a similar role in infected macrophages. Moreover, no
evidence to date has shown that AR-12 interacts directly
with PERK leading to its activation. Indeed, AR-12 has
been shown to inhibit the activities of PDF-1 and PAK-1
through interaction with their kinase domains, suggesting
that the activation of PERK activity is an indirect effect of
the drug. Based on the reported activities of celecoxib, the
compound from which AR-12 was derived, other poten-
tial targets of AR-12 include carbonic anhydrase, sarco-
plasmic/ER calcium ATPase (SERCA), COX-1 and COX-2
[42]. Among these enzymes, SERCA is interesting in that
it plays an important role in regulating [Ca2+] in the ER.
Inhibition of SERCA will cause Ca2+ efflux from ER to the
cytosol, leading to the unfolded protein response and sub-
sequent activation of PERK. Although there is no direct
evidence showing that AR-12 can interact with SERCA, the
cytosolic [Ca2+] of cancer cells increases immediately after
exposure to AR-12 which suggests that AR-12 may inhibit
SERCA activity [31]. Identification of the mechanism of
how AR-12 induces autophagy should facilitate the devel-
opment of more potent and specific host cell-targeted
antibacterial agents.
We recently reported that celecoxib, the parent compound
of AR-12, also exhibits anti-Francisella activity, and that
subsequent screening of a celecoxib-based focused com-
pound library identified Compound 20, a novel analog
with multi-fold greater antibacterial activity [31]. Unlike
AR-12, however, Compound 20 showed direct growth-
inhibitory activity against F. novicida and  F. tularensis
(Schu S4, a type A strain) at low μM concentrations. While
the intracellular growth of Francisella was also inhibited
by Compound 20, this occurred at concentrations that far
exceeded those shown for AR-12. Although the antibacte-
rial target of Compound 20 has not been identified, these
differences in activity suggest that Compound 20 and AR-
12 represent two novel classes of compound with distinct
antibacterial mechanisms. These findings highlight the
potential value of existing drugs as important sources of
lead compounds for the development of novel antibacte-
rial agents.
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